Allan Reine

Excited to welcome Svetlana Makhni as CFO of Prime Medicine. Svetlana brings deep biotech and financial leadership experience as we continue advancing Prime Editing and our mission for patients. Welcome to Prime!

CEO Allan Reine joined the Citizens Life Sciences and Jefferies conferences this week, including a fireside chat with Silvan Türkcan. Great opportunity to connect with the life sciences and investor community and share updates on the progress being driven across the team at Prime

Today we celebrate the women at Prime Medicine and across science and medicine, who drive innovation, collaboration, and progress every day. Thank you for pushing boundaries and shaping the future of gene editing. Happy International Women’s Day. #IWD2026 #WomenInScience

Last week, our team attended the @CF_Foundation 70th Annual Dinner, an inspiring evening honoring the CF community and the work driving progress forward. Proud to support and stand alongside this mission. #CysticFibrosis #CFAdvocay

Proud to share today’s update from the Prime Medicine team. This past year reflects the hard work and dedication behind advancing Prime Editing and moving our mission forward for patients. Grateful to everyone at Prime pushing the science and the vision every day. #PrimeMedicine #PrimeEditing #Leadership

Innovation begins with imagination. The latest work from @CIHR_IRSC is a powerful reminder of what’s possible when we dare to push science forward. At Prime Medicine, we’re inspired every day to help build a future where groundbreaking research transforms lives. Read more: cihr-irsc.gc.ca/e/54638.html

Below is the story of the first patient treated with a prime-edited therapeutic, developed by @PrimeMedicine in a trial led by Dr. Élie Haddad and his team at CHU Sainte-Justine. This teenager suffered from chronic granulomatous disease (CGD), an immunodeficiency, and now—10 months after treatment—the patient is healthy, stable, and living with a functioning immune system. Tracy Attebury, whose story was previously told by @ginakolata @nytimes, was the second patient treated with a prime-edited therapeutic. cihr-irsc.gc.ca/e/54638.html

Big congratulations to @davidrliu on his recognition in @TheWashingtonPost Next50. His vision fuels our mission at Prime Medicine to deliver precise, one‑time curative genetic therapies through Prime Editing. Excited for the future!

New Gene-Editing Strategy Could Help Development of Treatments for Rare Diseases nytimes.com/2025/11/19/hea… via @NYTimes

Today in @Nature we report a new prime editing strategy that can rescue a common cause of many genetic diseases in a disease-agnostic manner. This approach converts a redundant endogenous tRNA into an optimized suppressor tRNA, enabling a single prime edit to rescue premature stop codons across different diseases. (1/15) drive.google.com/file/d/1bSvkJW…

Harvard chemist and molecular biologist David Liu invented gene editing tools that can correct and rewrite defective genes. His research could one day help hundreds of millions of people with genetic diseases, including sickle cell and muscular dystrophy. cbsn.ws/4oyLApL

Today in @CellCellPress we report the use of prime editing to correct several mutations that cause alternating hemiplegia of childhood (AHC), a rare and devastating neurodevelopmental disorder, in patient-derived cells and in two mouse models. drive.google.com/file/d/1ibC50t… 1/10

Another medical milestone! The first patient treated with a prime edited therapeutic shows positive clinical outcomes consistent with effective rescue of his chronic granulomatous disease (CGD), a debilitating and life-shortening primary immunodeficiency. At least 19 base editing and prime editing clinical trials have begun, with at least 7 trials reporting clinical outcomes (highlighted in green in the table below). They treat a wide range of diseases both in vivo and ex vivo. And while the U.S. support for science is now in crisis, that there are more base editing and prime editing clinical trials serving patients outside of the U.S. (13) than within the U.S. (9), despite the fact that these technologies were developed in our lab in the U.S. investors.primemedicine.com/news-releases/…

Eli Lilly's Jake Van Naarden uncorked a deal to provide Flagship-backed Foghorn Therapeutics $380 million — $300 million in cash and $80 million for a premium equity deal — to jump on board the biotech’s development platform. endpts.com/eli-lillys-van…

We are delighted to announce a strategic collaboration with @Merck to discover and develop novel oncology therapeutics against a transcription factor target relevant to a broad range of #cancer patients. Learn more: bit.ly/38AGiUm

We had a groundbreaking party to celebrate the start of renovating our #newHQ. Thanks to Alexandria Real Estate Equities, @CBRE, @WiseBuilds and @Tria_Inc for making this project possible! Check back for updates as the renovation continues. #FogFam

At #JPM20, our president and CEO Adrian Gottschalk presented about our recent progress on advancing an entirely new class of medicines targeting the #chromatin regulatory system.

Come see our PRS-060 Phase 1b data poster presentation at #ERSCongress2019 tomorrow at 8:30am CEST! bit.ly/2nbSJTh